Contact us
About company
Roche Glycart develops antibody drug candidates, which include GA101, a humanized anti-CD20 monoclonal antibody to increase direct- and immune-mediated target cell death; and GA201, a humanized glycoengineered antibody for solid tumors.
CH
Unknown
Unknown
Not verified company
Business transparency
- Did not verified company info
- Ask their customers for reviews
- Did not replied to negative reviews